NCT00515203已完成1 期
A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects With Chronic Immune (Idiopathic) Thrombocytopenic Purpura
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 22
- 主要终点
- Adverse Events
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 1 Year 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Before any study-specific procedure, the appropriate written informed consent must be obtained. In addition to the written informed consent, the assent of the child from those subjects capable of providing assent must also be obtained if requested by the IRB/IEC.
- •Diagnosis of ITP according to The American Society of Hematology (ASH) Guidelines at least six months prior to screening
- •Age ≥ 12 months and < 18 years at enrollment
- •The mean of two platelet counts taken during the screening period must be ≤ 30 x 10^9/L with no single count >35 x 10^9/L
- •A serum creatinine concentration ≤ 1.5 times the laboratory normal range (for each age category)
- •Adequate liver function; serum bilirubin ≤ 1.5 times the laboratory normal range
- •Hemoglobin >10.0 g/dL
排除标准
- •Known history of a bone marrow stem cell disorder (any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study)
- •Known history of venous or arterial thrombotic or thromboembolic event
- •Known history of congenital thrombocytopenia
- •Known history of malignancy except basal cell carcinoma
- •Known history of hepatitis B, hepatitis C, or HIV
- •Known history of systemic lupus erythematosus, Evans Syndrome, or autoimmune neutropenia
- •Known positive lupus anticoagulant or history of antiphospholipid antibody syndrome
- •Known history of Disseminated Intravascular Coagulation, Hemolytic Uremic Syndrome, or Thrombotic Thrombocytopenic Purpura
- •Currently receiving any treatment for ITP except for corticosteroids
- •IV Ig or anti-D Ig within two weeks prior to the screening visit
- •Rituximab (for any indication) within 14 weeks before the screening visit or anticipated use during the time of the proposed study
- •Splenectomy within eight weeks of the screening visit
- •Received hematopoietic growth factors including IL-11 (oprelvekin) within four weeks before the screening visit
- •Received any alkylating agents within eight weeks before the screening visit or anticipated use during the time of the proposed study
- •Subject is currently enrolled in or has not yet completed at least four weeks since ending other investigational device or drug trial(s), or subject is receiving investigational agent(s)
- •Past or present participation in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), AMG 531, or related platelet product
- •Pregnant (i.e. positive urine pregnancy test) or breast feeding
- •Subject is not using adequate contraceptive precautions, if applicable.
- •Known hypersensitivity to any recombinant E coli-derived product
- •Subject has any kind of disorder that compromises the ability to comply with all study procedures
研究组 & 干预措施
II.
Placebo Comparator
5 thrombocytopenic (as defined per protocol) subjects
干预措施: Placebo (Drug)
I.
Experimental
15 thrombocytopenic (as defined per protocol) subjects
干预措施: AMG 531 (Drug)
结局指标
主要结局
Adverse Events
时间窗: 12 weeks
Occurrence of one or more adverse events in the participant during the 12-week treatment period
次要结局
- Weeks With Platelet Count ≥ 50 x 10^9/L(12-week treatment period)
- Bleeding Events (Grade 2 or Higher)(12-week treatment period (Weeks 2 - 13))
- Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks(12-week treatment period)
- Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks(12-week treatment period)
- Requirement for Rescue Therapy (as Defined Per Protocol)(12-week treatment period)
研究者
相似试验
已完成
2 期
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsMDSMyelodysplastic SyndromesThrombocytopeniaNCT00321711Amgen69
已完成
2 期
Study of Romiplostim(AMG531) in Subjects With Aplastic AnemiaAplastic AnemiaNCT02773290Kyowa Kirin Co., Ltd.46
已完成
1 期
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)Thrombocytopenic PurpuraNCT00117143Amgen16
已完成
3 期
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT02868099Kyowa Kirin China Pharmaceutical Co., Ltd.203
已完成
3 期
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)ThrombocytopeniaIdiopathic Thrombocytopenic PurpuraNCT00116688Amgen313